Novartis Announces Positive Phase III Trial Results for Ianalumab in Sjögren’s Disease
Novartis has reported that both of its pivotal Phase III clinical trials—NEPTUNUS-1 and NEPTUNUS-2—have successfully met their primary endpoint in adults with active Sjögren’s disease. These are the first global Phase III studies to show a statistically significant reduction in disease activity in this patient group. Trial Highlights What This Means for Patients About Ianalumab […]
Novartis Announces Positive Phase III Trial Results for Ianalumab in Sjögren’s Disease Read More »
